Alcohol Use Disorder (AUD) remains one of the world’s most devastating public health challenges, affecting over 280 million people and contributing to 5 percent of global deaths annually. Defined by compulsive drinking, loss of control, and withdrawal-related distress, AUD continues to defy lasting recovery for many. Although neuroscience has advanced, relapse rates remain around 60 to 70 percent within a year of treatment. Medications like naltrexone, acamprosate, and disulfiram—all approved decades ago—work reliably when used properly. Yet they remain underprescribed, as public attention drifts toward newer, more glamorous options like psychedelics.
Over the past few years, enthusiasm for psilocybin, LSD, and MDMA has surged in psychiatry, with headlines touting their potential to revolutionize mental health care. While there is growing evidence that psychedelics may help conditions like depression, anxiety, and PTSD, their role in treating alcohol addiction is still highly uncertain. Dr. A. Benjamin Srivastava of Columbia University and his colleagues caution that optimism is outpacing data. “We have solid, well-tested treatments for AUD,” he explains, “but they’re vastly underutilized. The evidence for psychedelics is preliminary and riddled with methodological flaws. What we don’t want is patients self-medicating with psilocybin while ignoring medications that are safe, accessible, and effective.”
The idea of using psychedelics for addiction is not new. In the 1950s and 60s, psychiatrists Humphry Osmond and Abram Hoffer experimented with LSD to treat alcoholism, hoping to replicate the “spiritual awakening” described in Alcoholics Anonymous recovery stories. Their early results appeared promising, but the studies lacked scientific rigor—no randomization, inconsistent measures, and small sample sizes. Even AA co-founder Bill Wilson, once intrigued by the approach, eventually distanced himself from it.
Modern clinical trials have not dramatically changed that picture. A phase 2 study by Michael Bogenschutz and colleagues found that psilocybin-assisted therapy slightly reduced heavy drinking—but the benefit appeared only in the final month of a 36-week trial, after most measures showed no difference compared to placebo. Furthermore, nearly 90 percent of participants guessed which treatment they had received, undermining the study’s blinding. As Srivastava and others point out, such trials suggest promise but fall far short of proving psychedelics outperform established therapies.
Where psychedelics might eventually help is in refractory or severe cases of AUD—particularly when combined with psychotherapy. Some hypotheses suggest that psychedelics enhance neuroplasticity, enabling patients to reprocess identity, memory, and self-concept in ways traditional medications cannot. Still, current data are insufficient to recommend psychedelics as replacements or even adjuncts to standard care.
Meanwhile, the medications we already have remain the most evidence-based tools for recovery. Naltrexone reduces the reward effects of alcohol and can be taken orally or via monthly injection (Vivitrol), which helps improve adherence. Acamprosate supports long-term abstinence by balancing brain chemistry disrupted by chronic drinking. Disulfiram (Antabuse) creates an intense physical reaction when alcohol is consumed, reinforcing sobriety through aversive conditioning. Despite proven effectiveness, fewer than 2 percent of people with AUD receive these medications—a staggering gap driven by stigma, limited physician training, and lack of awareness.
Recent innovations may close that gap. Telehealth and direct-to-consumer prescription models—similar to how Viagra first reached patients—now allow people to obtain naltrexone discreetly. Harvard and Mass General researchers have even proposed making oral naltrexone available over the counter to reduce heavy drinking, much like nicotine patches for smoking cessation. Such steps could normalize medication-based treatment and dramatically expand access to care.
Psychedelics, in contrast, are still in the experimental phase. Their effects on mood, cognition, and brain networks are being actively studied in depression, OCD, PTSD, and end-of-life distress, with encouraging early results. For these conditions, psilocybin and LSD show potential to “reset” rigid thought patterns and enhance emotional processing. But with AUD, the story is different. Alcohol addiction involves deeply entrenched reward pathways, genetic factors, and social components that psychedelics have yet to address convincingly.
The bottom line is that psychedelics are fascinating tools—but not magic bullets. Their scientific promise in treating depression or trauma is genuine, yet their application to alcohol use disorder remains speculative. With AUD, clinicians already possess effective interventions that save lives. The real challenge is not discovering something new, but using what already works.
For now, the best approach combines medication, behavioral therapy, and community support such as Alcoholics Anonymous, which research shows significantly improves long-term abstinence when paired with pharmacological treatment. Psychedelics may one day play a role for select cases, but today, the evidence says no. The priority must remain clear: deploy proven treatments, expand access, and resist the temptation to replace science with hype.
